Sifat Jubaira/LinkedIn
Feb 15, 2026, 10:26
Sifat Jubaira: K₂-EDTA vs K₃-EDTA – Same Anticoagulant, Very Different Accuracy
Sifat Jubaira, Lab Medicine Specialist at United Hospital Limited, shared a post on LinkedIn:
“K₂-EDTA vs K₃-EDTA – Same Anticoagulant, Very Different Accuracy
Both K₂-EDTA and K₃-EDTA prevent blood clotting by binding calcium.
But their impact on hematology results is not the same.
K₂-EDTA (Dipotassium EDTA)
- Dry, spray-coated
- No dilution effect
- Preserves RBC size and platelet count
- Gold standard for CBC
K₃-EDTA (Tripotassium EDTA)
- Liquid leads to sample dilution
- May falsely decrease Hb, Hct, MCV and platelets
- Alters cell morphology
- No longer recommended for routine hematology
Bottom line:
For accurate hematological values and reliable cell morphology, K₂-EDTA is the anticoagulant of choice.
Authentic References
- ICSH Guidelines – Recommendations for EDTA anticoagulants in hematology
- CLSI GP34 / H21 – Collection, transport and processing of blood specimens
- Bain BJ. Blood Cells: A Practical Guide, Wiley-Blackwell
- Dacie and Lewis. Practical Haematology, Elsevier”
Find more posts featuring Sifat Jubaira on Hemostasis Today.
-
Jul 10, 2026, 20:47New Machine Learning Models Improve Prediction of Thrombosis and Bleeding in Cancer – JTH
-
Jul 10, 2026, 20:39Evangelia Petsalaki: New Systems Biology Approach Identifies Biomarkers in Thrombotic APS
-
Jul 10, 2026, 20:29Wolfgang Miesbach: Celebrating Pantep Angchaisuksiri’s Transformative Leadership of the ISTH
-
Jul 10, 2026, 20:17Amy Pantaleo: How Staffing Shortages Are Changing Hemostasis Laboratories
-
Jul 10, 2026, 20:15Gene Nudelman: Early Hemorrhage Control Improves Patient Outcomes
-
Jul 10, 2026, 20:15Lee G.: Can We Transform Dengue Patient Management with Better Coagulation Assessment?
-
Jul 10, 2026, 20:13Shahin Alam: Is Your Coagulant Limiting Your Water Treatment Performance?
-
Jul 10, 2026, 20:12Ali Bozorgi: Our Meta-Analysis on Oral Anticoagulation After AF Ablation Featured in EP Europace
-
Jul 10, 2026, 15:34Joy Celebre: A New Opportunity in Hemostasis Leadership